BioMarin Pharmaceutical Inc. (BMRN)
BMRN moved a median of -0.08% 30 minutes after news, and -0.09% by the close. How BMRN actually reacts to news — the realized, point-in-time move the market made, measured across 356 labeled events over the last three years with zero look-ahead.
BMRN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.03% | 48% | 354 |
| 30-min | -0.08% | 45% | 355 |
| 60-min | -0.08% | 46% | 356 |
| to close | -0.09% | 47% | 354 |
| Middle 50% of BMRN reactions | -0.54% to +0.54% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 356 |
Half of all BioMarin Pharmaceutical Inc. news events land between -0.54% and +0.54% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BMRN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 31 | -0.10% | 36% | +0.19% |
| Analyst downgrades | 20 | +0.14% | 65% | -0.20% |
| Coverage initiations | 27 | -0.18% | 44% | -1.02% |
| Rating reiterations | 150 | -0.01% | 47% | -0.34% |
| Price-target raises | 34 | +0.17% | 59% | -0.63% |
| Price-target cuts | 45 | -0.18% | 40% | -0.56% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how BMRN ranks against every other measured name →
That’s how BMRN usually reacts — get an email when it moves on news →Email me when BMRN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BMRN's baseline. Nothing else.
Recent BMRN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting | Press release | PR Newswire | +0.12% | -0.01% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -0.90% | -1.60% | |
| BioMarin Appoints Cara Bauer as Chief People Officer | Press release | PR Newswire | -0.09% | -2.29% | |
| BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress | Press release | PR Newswire | -0.03% | -1.58% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | -2.40% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | -2.02% | |
| BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors | Press release | PR Newswire | +0.03% | -0.17% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | -0.17% | |
| BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence | Press release | PR Newswire | +0.77% | +0.91% | |
| BioMarin to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +1.95% | +3.03% | |
| BioMarin Announces Close of the Alesta Therapeutics Acquisition | Press release | PR Newswire | +0.58% | -1.07% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | +0.58% | -1.07% | |
| BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea | Press release | PR Newswire | -2.07% | -1.09% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 30 | SEC filing · Form 8-K | SEC EDGAR | -2.07% | -1.09% | |
| BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline | Press release | PR Newswire | +0.16% | -0.33% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -0.33% | |
| BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston | Press release | PR Newswire | +1.02% | — | |
| BioMarin Reports Second Quarter 2026 Financial and Operating Results | Press release | PR Newswire | -1.54% | -1.68% | |
| Form 10-Q BIOMARIN PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.54% | -1.68% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -1.54% | -1.68% | |
| Form S-8 BIOMARIN PHARMACEUTICAL | SEC filing · Form S-8 | SEC EDGAR | -1.54% | -1.68% | |
| BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET | Press release | PR Newswire | +0.31% | -0.03% | |
| BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome | Press release | PR Newswire | -0.28% | +0.63% | |
| Form 8-K/A BIOMARIN PHARMACEUTICAL For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -0.79% | +0.33% | |
| U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia | Press release | PR Newswire | -0.86% | +0.14% | |
| BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 | Press release | PR Newswire | -0.48% | -0.95% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | +1.21% | |
| BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia | Press release | PR Newswire | +1.74% | +3.60% | |
| BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | Press release | PR Newswire | -0.21% | -3.76% | |
| 4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors | Press release | Business Wire | +1.71% | -4.25% | |
| Form 10-Q BIOMARIN PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.64% | -0.52% | |
| BioMarin Reports First Quarter 2026 Financial and Operating Results | Press release | PR Newswire | +1.71% | -4.25% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +1.71% | -4.25% | |
| BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting | Press release | PR Newswire | +1.53% | +3.35% | |
| BioMarin Completes Acquisition of Amicus Therapeutics | Press release | PR Newswire | -0.38% | +0.21% | |
| BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET | Press release | PR Newswire | -0.38% | +0.21% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -0.38% | +0.21% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | -0.76% | -1.28% | |
| BioMarin Announces Board Leadership Transition | Press release | PR Newswire | -0.33% | -1.10% | |
| Form ARS BIOMARIN PHARMACEUTICAL For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.33% | -1.10% | |
| Form DEF 14A BIOMARIN PHARMACEUTICAL For: Jun 02 | SEC filing · Form DEF | SEC EDGAR | -0.33% | -1.10% | |
| Form DEFA14A BIOMARIN PHARMACEUTICAL | SEC filing · Form DEFA14A | SEC EDGAR | -0.33% | -1.10% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +3.60% | +1.27% | |
| BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics M | Press release | PR Newswire | -0.37% | -1.52% | |
| U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) | Press release | PR Newswire | +0.41% | -1.60% | |
| Form 10-K BIOMARIN PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.18% | +1.13% | |
| BioMarin to Participate in Four Upcoming Investor Conferences in March | Press release | PR Newswire | +8.96% | +3.85% | |
| BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results | Press release | PR Newswire | +8.96% | +3.85% | |
| Form 8-K BIOMARIN PHARMACEUTICAL For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +8.96% | +3.85% | |
| Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight | Press release | PR Newswire | -1.02% | +2.90% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BMRN section they belong to.
Where else BMRN is measured.
BMRN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Hologic, Inc. (HOLX) | 357 | -0.00% | 44% |
| BioCardia, Inc. (BCDA) | 356 | -0.06% | 44% |
| McKesson Corporation (MCK) | 355 | +0.02% | 53% |
| Owens & Minor, Inc. (OMI) | 355 | -0.48% | 34% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioMarin Pharmaceutical Inc.'s median reaction calculated?
Every labeled BMRN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 356 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of BMRN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BMRN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.